Associations Between SNPs Within Antioxidant Genes and the Risk of Prostate Cancer in the Siberian Region of Russia

Abstract

In the present study we investigated the association of a number of polymorphic changes in antioxidant system genes (SNPs rs1050450 in the GPX1 gene, rs1695 and rs1138272 in the GSTP1 gene and rs4880 in the MnSOD gene) with the risk of prostate cancer. The association of disease stage and PSA levels with specific genotypes was also analyzed. A study was conducted with the participation of 736 Russian men. We compared the frequency of occurrence of the studied alleles in patients with prostate cancer (392) to a control group (344) of men without a history of cancer. Genotyping was performed by real-time PCR. Comparison of frequencies of alleles and genotypes were performed using logistic regression analysis. No statistically significant association with the risk of prostate cancer was found for any of the SNPs studied (p > 0.05). For SNP rs1695 in the GSTP1 gene, a correlation with cancer disease stage was observed: a GG genotype is significantly more common in patients with PCa in the 3rd and 4th stage than 1st and 2nd (OR[95%CI] = 2.66[1.15-6.18], p = 0.02). Both studied SNPs of GSTP1 gene are associated with the level of PSA: the GG rs1695 and the TT rs1138272 genotypes are associated with higher PSA levels (p = 1.5*10(-3)).

Association betweenMnSODVal16Ala Polymorphism and Cancer Risk: Evidence from 33,098 Cases and 37,831 Controls

“…Overall, 88 studies with 33,098 cases and 37,831 controls were included in this meta-analysis. Of the 88 studies, 24 studies focused on breast cancer [ 9 – 11 , 16 , 38 , 60 , 61 , 68 , 69 , 71 , 72 , 77 , 88 , 93 , 96 , 97 , 100 , 105 , 109 , 114 , 119 , 122 , 127 ]; 17 on prostate cancer [ 37 , 66 , 74 , 79 , 82 , 85 , 86 , 89 , 95 , 106 , 111 , 113 , 120 , 125 , 128 ]; six for each of the following cancer types, such as lung cancer [ 7 , 17 , 18 , 65 , 92 , 118 ], bladder cancer [ 8 , 15 , 67 , 75 , 112 , 117 ], and pancreatic cancer [ 64 , 91 , 102 , 107 , 108 , 121 ]; five on colorectal cancer [ 13 , 63 , 73 , 94 , 101 ]; three for each of the following cancer types, such as ovarian cancer [ 70 , 81 , 87 ], hepatocellular carcinoma [ 98 , 99 , ...…”

Association between Manganese Superoxide Dismutase (MnSOD) Polymorphism and Prostate Cancer Susceptibility: A Meta-Analysis

“…Recently, it has been demonstrated that a T-to-C substitution in the SOD2 gene could result in a valine (Val) to alanine (Ala) amino acid change, thus causing higher MnSOD enzymatic activity. Moreover, a growing number of studies have discovered a connection between the MnSOD Val16Ala polymorphism (rs4880) and the risk of PCa (16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30). Therefore, this single-nucleotide polymorphism might play an important role in prostate carcinogenesis.…”

Comprehensive Analysis of the Association Between the rs1138272 Polymorphism of the GSTP1 Gene and Cancer Susceptibility

“…An additional 56 articles were excluded, including 56 articles with unavailable data on the genotype frequency of CC, CT, and TT within GSTP1 rs1138272, and 4 articles in which the data were not in HWE. After a quality evaluation, 40 articles (Harris et al, 1998; Saarikoski et al, 1998; Park et al, 1999; Wadelius et al, 1999; Welfare et al, 1999; Marshall et al, 2000; Stanulla et al, 2000; Krajinovic et al, 2002; Wang et al, 2003, 2011; Sorensen et al, 2004; Yang et al, 2004; Garcia-Closas et al, 2005; Landi et al, 2005, 2007; Moore et al, 2005; De Roos et al, 2006; Lira et al, 2006; Marciniak et al, 2006; Jiao et al, 2007; Li et al, 2007, 2010; Murphy et al, 2007; Al-Dayel et al, 2008; Kury et al, 2008; Siraj et al, 2008; Van Emburgh et al, 2008; Zienolddiny et al, 2008; Canova et al, 2009; Northwood et al, 2010; Sainz et al, 2011; Ebrahimkhani et al, 2012; Garcia-Gonzalez et al, 2012; Ibarrola-Villava et al, 2012; Dura et al, 2013; Oskina et al, 2014; Ghatak et al, 2016; De Mattia et al, 2017; Minina et al, 2017; Rajesh et al, 2018) of good quality were included. Finally, we included a total of 43 case-control studies for our quantitative synthesis.…”

“…We removed one case-control study in which the data were not in HWE (Marie-Genica Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk, 2010), and we removed two additional studies (Barnette et al, 2004) because they failed to meet the requirement of reporting the genotype frequency in both the case and control group. Moreover, 17 new articles (Park et al, 1999; Welfare et al, 1999; Marshall et al, 2000; Stanulla et al, 2000; Krajinovic et al, 2002; De Roos et al, 2006; Lira et al, 2006; Li et al, 2007, 2010; Sainz et al, 2011; Garcia-Gonzalez et al, 2012; Dura et al, 2013; Oskina et al, 2014; Ghatak et al, 2016; De Mattia et al, 2017; Minina et al, 2017; Rajesh et al, 2018) were added. Finally, a total of 40 articles were included in our updated meta-analysis.…”